Role of Calcineurin-Dependent Signaling Pathway on the Left Ventricular Hypertrophy Induced by Pressure Overload

Background and Objectives:Calcineurin-dependent transcriptional pathway has recently been implicated in cardiac hypertrophy. Whether calcineurin inhibition can prevent the development of pressure-overload left ventricular hypertrophy (LVH is still controversial. To elucidate this issue, the effects of calcineurin inhi- bitors on the prevention of pressure-overload LVH were examined in mice. Materials and Methods:Pressure overload was induced by transverse aortic contriction (TAC in 57 ICR mice. Three different doses of CsA (TAC/CsA group, n=21 and FK506 (TAC/FK group, n=20 were administered subcutaneously from -2 to 14 days after surgery and 16 mice were treated with vehicle (TAC group. Another 60 mice were sham-operated and treated with CsA (CsA group, n=19, FK506 (FK group, n=18 or vehicle (Control group, n=23. Results:Two weeks after TAC, the LV weight-to-body weight (LVW/BW ratio was not significantly diff- erent among the Control, CsA and FK groups although it was greater in the TAC group (4.55±0.69 mg/g than in the Control (2.78±0.70 mg/g and other sham-operated groups (p<0.00005. Low-dose CsA (5 mg/ kg/day or FK506 (0.6 mg/kg/day injection following TAC did not decrease the LVW/BW ratio. However, intermediate-dose and high-dose CsA (25 and 50 mg/kg/day or FK506 (2 and 6 mg/kg/day treatment preve- nted pressure-overload induced LVH and the degree of LVH inhibition was dose-dependent. Interstitial and/or perivascular fibrosis was remarkably decreased by the administration of intermediate and high doses of cal- cineurin inhibitors for 2 weeks following TAC. Conclusion:Taken together, calcineurin inhibitors, CsA and FK506, attenuated pressure-overload LVH response in a dose-dependent fashion. This data indicates that a

[1]  S. Vatner,et al.  Cyclosporine reduces left ventricular mass with chronic aortic banding in mice, which could be due to apoptosis and fibrosis. , 2001, Journal of molecular and cellular cardiology.

[2]  M. Hori,et al.  Calcineurin Inhibitor Attenuates Left Ventricular Hypertrophy, Leading to Prevention of Heart Failure in Hypertensive Rats , 2000, Circulation.

[3]  E. Olson,et al.  Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. , 1999, Circulation research.

[4]  E. Olson,et al.  Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. , 1999, Circulation research.

[5]  K. Walsh,et al.  Calcineurin inhibitors and cardiac hypertrophy , 1998, Nature Medicine.

[6]  Mark A Sussman,et al.  Prevention of cardiac hypertrophy in mice by calcineurin inhibition. , 1998, Science.

[7]  Jeffrey Robbins,et al.  A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.

[8]  B. A. Harder,et al.  Various hypertrophic stimuli induce distinct phenotypes in cardiomyocytes , 1997, Journal of Molecular Medicine.

[9]  C. Long.  Autocrine and Paracrine Regulation of Myocardial Cell Growth in Vitro The TGFβ Paradigm. , 1996, Trends in cardiovascular medicine.

[10]  J. Towbin,et al.  Gene mapping of familial autosomal dominant dilated cardiomyopathy to chromosome 10q21-23. , 1996, The Journal of clinical investigation.

[11]  S. Vatner,et al.  Adverse Effects of Chronic Endogenous Sympathetic Drive Induced by Cardiac Gsα Overexpression , 1996 .

[12]  R Aikawa,et al.  Endothelin-1 Is Involved in Mechanical Stress-induced Cardiomyocyte Hypertrophy (*) , 1996, The Journal of Biological Chemistry.

[13]  L. Makowka,et al.  A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation: The U.S. Multicenter FK506 Liver Study Group. N Engl J Med 1994;331:1110–1115 , 1995 .

[14]  P. Poole‐Wilson,et al.  Cellular mechanisms of cardiac hypertrophy. , 1995, British heart journal.

[15]  J. Sadoshima,et al.  Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro , 1993, Cell.

[16]  A. Means,et al.  Targeted developmental overexpression of calmodulin induces proliferative and hypertrophic growth of cardiomyocytes in transgenic mice. , 1993, Endocrinology.

[17]  W Grossman,et al.  Expression of dihydropyridine receptor (Ca2+ channel) and calsequestrin genes in the myocardium of patients with end-stage heart failure. , 1992, The Journal of clinical investigation.

[18]  S. Chien,et al.  Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  K. Baker,et al.  Cardiac Hypertrophy: Mechanical, Neural, and Endocrine Dependence , 1991 .

[20]  D. Levy,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[21]  T. Parker,et al.  Cardiac Myocytes as Targets for the Action of Peptide Growth Factors , 1990, Circulation.

[22]  A. Katz.  Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure. , 1990, The New England journal of medicine.

[23]  C. Long,et al.  Alpha 1-adrenergic receptor stimulation of sarcomeric actin isogene transcription in hypertrophy of cultured rat heart muscle cells. , 1989, The Journal of clinical investigation.

[24]  H. Eppenberger,et al.  Immunocytochemical analysis of the regeneration of myofibrils in long-term cultures of adult cardiomyocytes of the rat. , 1988, Developmental biology.

[25]  K. Chien,et al.  Alpha 1-adrenergic stimulation of cardiac gene transcription in neonatal rat myocardial cells. Effects on myosin light chain-2 gene expression. , 1988, The Journal of biological chemistry.

[26]  A. Nag,et al.  Biochemical evidence for cellular dedifferentiation in adult rat cardiac muscle cells in culture: expression of myosin isozymes. , 1986, Biochemical and biophysical research communications.

[27]  G. Dorn,et al.  Cytoplasmic signaling pathways that regulate cardiac hypertrophy. , 2001, Annual review of physiology.

[28]  P. Hogan,et al.  Transcription factors of the NFAT family: regulation and function. , 1997, Annual review of immunology.

[29]  J. Sadoshima,et al.  The cellular and molecular response of cardiac myocytes to mechanical stress. , 1997, Annual review of physiology.

[30]  Linda Sher,et al.  A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. , 1994, The New England journal of medicine.

[31]  K. Chien,et al.  Transcriptional regulation during cardiac growth and development. , 1993, Annual review of physiology.